Summary
0.60 0.00(0.79%)05/17/2024
23andMe Holding Co (ME)
23andMe Holding Co (ME)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.11 | -0.98 | 5.09 | -31.97 | -45.80 | -77.14 | 0.00 | -85.69 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 0.49 | |
| Open | 0.48 | |
| High | 0.51 | |
| Low | 0.48 | |
| Volume | 3,084,186 | |
| Change | 0.01 | |
| Change % | 1.11 | |
| Avg Volume (20 Days) | 7,953,167 | |
| Volume/Avg Volume (20 Days) Ratio | 0.39 | |
| 52 Week Range | 0.35 - 2.21 | |
| Price vs 52 Week High | -77.66% | |
| Price vs 52 Week Low | 41.09% | |
| Range | 2.88 | |
| Gap Up/Down | -0.05 | |
Fundamentals | ||
| Market Capitalization (Mln) | 299 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 13.50 | |
| Book Value | 1.6200 | |
| Earnings Per Share | -1.2120 | |
| EPS Estimate Current Quarter | -0.1100 | |
| EPS Estimate Next Quarter | -0.1300 | |
| EPS Estimate Current Year | 0.0000 | |
| EPS Estimate Next Year | -0.5700 | |
| Diluted EPS (TTM) | -1.2120 | |
| Revenues | ||
| Profit Marging | -0.6584 | |
| Operating Marging (TTM) | -0.7745 | |
| Return on asset (TTM) | -0.2426 | |
| Return on equity (TTM) | -1.1199 | |
| Revenue TTM | 258,502,000 | |
| Revenue per share TTM | 1.8410 | |
| Quarterly Revenue Growth (YOY) | 0.0660 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 117,006,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.3065 | |
| Revenue Enterprise Value | 11.8373 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 123,705,000 | |
| Shares Float | 106,491,724 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 5.02 | |
| Institutions (%) | 33.79 | |
05/16 12:15 EST - accesswire.com
23andMe Holding Co (NASDAQ: ME) Jewish and Chinese Users
NEW YORK, NY / ACCESSWIRE / May 16, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
23andMe Holding Co (NASDAQ: ME) Jewish and Chinese Users
NEW YORK, NY / ACCESSWIRE / May 16, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
05/16 12:15 EST - accesswire.com
Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach
NEW YORK, NY / ACCESSWIRE / May 16, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach
NEW YORK, NY / ACCESSWIRE / May 16, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
05/14 12:15 EST - accesswire.com
DATA BREACH - 23andMe Jewish & Chinese Consumers May be Affected
NEW YORK, NY / ACCESSWIRE / May 14, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
DATA BREACH - 23andMe Jewish & Chinese Consumers May be Affected
NEW YORK, NY / ACCESSWIRE / May 14, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
05/14 09:15 EST - accesswire.com
Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe
Lemonaid Health will offer customers more affordable access to branded ED medication STENDRA that may be taken as early as ~15 minutes prior to sexual activity (100mg and 200mg strengths only) [1] Please see Important Safety Information and study design below NEW YORK, NY / ACCESSWIRE / May 14, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces the availability of all strengths of the Company's prescription erectile dysfunction (ED) medication, STENDRA (avanafil) on the telehealth platform Lemonaid Health, Inc. Lemonaid Health is a subsidiary of 23andMe Holding Co. (Nasdaq: ME), and a leading telemedicine provider. "With Lemonaid's nationwide distribution and industry leading track record of treating a significant number of ED patients across the country, we are excited to collaborate with Lemonaid Health in this expanded access initiative for STENDRA.
Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe
Lemonaid Health will offer customers more affordable access to branded ED medication STENDRA that may be taken as early as ~15 minutes prior to sexual activity (100mg and 200mg strengths only) [1] Please see Important Safety Information and study design below NEW YORK, NY / ACCESSWIRE / May 14, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces the availability of all strengths of the Company's prescription erectile dysfunction (ED) medication, STENDRA (avanafil) on the telehealth platform Lemonaid Health, Inc. Lemonaid Health is a subsidiary of 23andMe Holding Co. (Nasdaq: ME), and a leading telemedicine provider. "With Lemonaid's nationwide distribution and industry leading track record of treating a significant number of ED patients across the country, we are excited to collaborate with Lemonaid Health in this expanded access initiative for STENDRA.
05/14 07:00 EST - globenewswire.com
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
Lemonaid Health will offer customers more affordable access to fast-acting branded ED medication that works as quickly as 15 minutes prior to sexual activity Lemonaid Health will offer customers more affordable access to fast-acting branded ED medication that works as quickly as 15 minutes prior to sexual activity
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
Lemonaid Health will offer customers more affordable access to fast-acting branded ED medication that works as quickly as 15 minutes prior to sexual activity Lemonaid Health will offer customers more affordable access to fast-acting branded ED medication that works as quickly as 15 minutes prior to sexual activity
05/10 12:15 EST - accesswire.com
DATA BREACH- 23andMe Jewish & Chinese Consumers May be Affected
NEW YORK, NY / ACCESSWIRE / May 10, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
DATA BREACH- 23andMe Jewish & Chinese Consumers May be Affected
NEW YORK, NY / ACCESSWIRE / May 10, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
05/09 16:50 EST - globenewswire.com
23andMe to Report Q4 and Full Year FY2024 Financial Results
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fourth quarter and full fiscal year 2024 (FY2024) after the market closes on Thursday, May 23, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter and year's financial results and report on business progress.
23andMe to Report Q4 and Full Year FY2024 Financial Results
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fourth quarter and full fiscal year 2024 (FY2024) after the market closes on Thursday, May 23, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter and year's financial results and report on business progress.
05/07 12:15 EST - accesswire.com
23andMe Data Breach - Hackers Targeted Jewish and Chinese Users Data
NEW YORK, NY / ACCESSWIRE / May 7, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
23andMe Data Breach - Hackers Targeted Jewish and Chinese Users Data
NEW YORK, NY / ACCESSWIRE / May 7, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.
04/24 16:05 EST - globenewswire.com
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Data from neuroendocrine and ovarian cancer patient cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented Data from neuroendocrine and ovarian cancer patient cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Data from neuroendocrine and ovarian cancer patient cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented Data from neuroendocrine and ovarian cancer patient cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented
04/23 05:21 EST - fool.com
This Technology Company Is Being Acquired at a Shocking 207% Premium -- and These 2 Stocks Could Be Next
Matterport is being acquired by CoStar in a $1.7 billion cash and stock deal. The company not only has an excellent proprietary technology, but also a strong balance sheet.
This Technology Company Is Being Acquired at a Shocking 207% Premium -- and These 2 Stocks Could Be Next
Matterport is being acquired by CoStar in a $1.7 billion cash and stock deal. The company not only has an excellent proprietary technology, but also a strong balance sheet.
04/18 19:00 EST - fastcompany.com
23andMe wants to go private. It's the latest in a line of failed SPACs
Like a number of companies that went public during the pandemic, 23andMe has for months been trying to manage a terrible case of SPAC-itis, an inflammation that causes plunging stock values due to the business being, as one analyst put it, not “ready for prime time.”
23andMe wants to go private. It's the latest in a line of failed SPACs
Like a number of companies that went public during the pandemic, 23andMe has for months been trying to manage a terrible case of SPAC-itis, an inflammation that causes plunging stock values due to the business being, as one analyst put it, not “ready for prime time.”
04/18 11:51 EST - proactiveinvestors.com
23andMe CEO reveals take-private plan
23andMe Holding Co.'s shares surged after CEO Anne Wojcicki revealed plans to potentially take the struggling DNA testing firm private. The announcement follows the company's dismal performance since going public three years ago, with shares plummeting by over 90% amid sluggish adoption of its personalized DNA services.
23andMe CEO reveals take-private plan
23andMe Holding Co.'s shares surged after CEO Anne Wojcicki revealed plans to potentially take the struggling DNA testing firm private. The announcement follows the company's dismal performance since going public three years ago, with shares plummeting by over 90% amid sluggish adoption of its personalized DNA services.
04/18 10:44 EST - investorplace.com
ME Stock Alert: CEO Anne Wojcicki Seeks to Save 23andMe in Take-Private Deal
23andMe (NASDAQ: ME ) stock is on the move Thursday after CEO Anne Wojcicki proposed taking the consumer genetics testing company private. A filing with the Securities and Exchange Commission (SEC) reveals that Wojcicki notified members of the Board of Directors Special Committee about such a plan on April 13.
ME Stock Alert: CEO Anne Wojcicki Seeks to Save 23andMe in Take-Private Deal
23andMe (NASDAQ: ME ) stock is on the move Thursday after CEO Anne Wojcicki proposed taking the consumer genetics testing company private. A filing with the Securities and Exchange Commission (SEC) reveals that Wojcicki notified members of the Board of Directors Special Committee about such a plan on April 13.
04/18 10:30 EST - investopedia.com
23andMe CEO Wojcicki Plans To Take DNA-Testing Firm Private
23andMe (ME) chief executive Anne Wojcicki is seeking to take the DNA-testing company private less than three years after it went public, the firm said in a Securities and Exchange Commission (SEC) filing.
23andMe CEO Wojcicki Plans To Take DNA-Testing Firm Private
23andMe (ME) chief executive Anne Wojcicki is seeking to take the DNA-testing company private less than three years after it went public, the firm said in a Securities and Exchange Commission (SEC) filing.
04/18 10:07 EST - cnbc.com
23andMe CEO Anne Wojcicki considers taking company private
23andMe CEO Anne Wojcicki is considering a proposal to take the genetic testing company private
23andMe CEO Anne Wojcicki considers taking company private
23andMe CEO Anne Wojcicki is considering a proposal to take the genetic testing company private
04/18 08:00 EST - globenewswire.com
23andMe announces CEO's intention to pursue a potential take-private
SOUTH SAN FRANCISCO, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, has been made aware that Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, is considering making a proposal to acquire all of the outstanding shares of 23andMe that she does not currently own, as she stated in an amendment dated April 17, 2024 to her Schedule 13D filing with the Securities and Exchange Commission. Ms. Wojcicki currently owns shares constituting more than 20% of the total outstanding shares and entitling her to approximately 49% of the voting power of the total outstanding shares of 23andMe. Ms. Wojcicki also indicated in her Schedule 13D filing that she wishes to maintain control of 23andMe and, therefore, will not be willing to support any alternative transaction.
23andMe announces CEO's intention to pursue a potential take-private
SOUTH SAN FRANCISCO, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, has been made aware that Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, is considering making a proposal to acquire all of the outstanding shares of 23andMe that she does not currently own, as she stated in an amendment dated April 17, 2024 to her Schedule 13D filing with the Securities and Exchange Commission. Ms. Wojcicki currently owns shares constituting more than 20% of the total outstanding shares and entitling her to approximately 49% of the voting power of the total outstanding shares of 23andMe. Ms. Wojcicki also indicated in her Schedule 13D filing that she wishes to maintain control of 23andMe and, therefore, will not be willing to support any alternative transaction.